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ABSTRACT
The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). 
It accounts for 70-80% of all renal malignancies representing the third most common 
urological cancer after prostate and bladder cancer. The identification of non-invasive 
biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent 
a relevant step-forward in ccRCC management. The aim of this study is to evaluate 
whether specific miRNAs deregulated in ccRCC tissues present altered levels also 
in urine specimens. To this end we first assessed that miR-21-5p, miR-210-3p and 
miR-221-3p resulted upregulated in ccRCC fresh frozen tissues compared to matched 
normal counterparts. Next, we evidenced that miR-210-3p resulted significantly up-
regulated in 38 urine specimens collected from two independent cohorts of ccRCC 
patients at the time of surgery compared to healthy donors samples. Of note, miR-
210-3p levels resulted significantly reduced in follow-up samples. These results point 
to miR-210-3p as a potential non-invasive biomarker useful not only for diagnosis 
but also for the assessment of complete resection or response to treatment in ccRCC 
management.
INTRODUCTION
Renal cell carcinoma (RCC) represents 2-3% of 
adult malignancies [1], with a peak of incidence occurring 
between 60 and 70 years and a 3:2 male:female ratio 
[2]. The clear cell RCC (ccRCC) is the most common 
subtype of RCC and represents the third most common 
urological cancer after prostate and bladder cancer. The 
incidence of the disease has been steadily rising in Europe 
to over 30,000 new cases per year and its mortality rate 
has reached 40% [3]. The early diagnosis and complete 
surgical excision are the main factors contributing to a 
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definitive treatment of ccRCC. Surgery represents the 
most important therapeutic option for ccRCC management 
[4], but nephrectomy of the primary tumor is curative 
only if the tumor is still localized in the kidney. Thus, for 
patients with advanced and metastatic ccRCC, surgery is 
often palliative [5]. Targeted therapy has recently emerged 
in ccRCC management considering also that ccRCC is 
usually resistant to both chemotherapy and radiotherapy. 
Tyrosine kinases or mTOR pathways inhibitors are drugs 
often used in advanced RCC [6, 7]; however, resistance 
frequently occurs after these targeted therapies [8]. A key 
challenge for the improvement of ccRCC management 
could derive from a deeper molecular characterization of 
this neoplasm that could greatly improve the diagnosis, 
prognosis and treatment choice [9]. The comprehension 
of microRNAs (miRNAs) contribution to tumorigenesis 
and the identification of miRNAs as potential biomarkers 
for diagnosis and therapy response are becoming relevant 
for cancer management [10, 11]. To date, a number 
of studies identified miRNAs differentially expressed 
between normal and neoplastic tissues in ccRCC as well 
as miRNAs secreted into blood and urine, suggesting 
that these small molecules may serve as non-invasive 
diagnostic, prognostic and surveillance markers in 
urological carcinomas [12–17]. The urinary miR-210 is 
currently under investigation as a potential tool for ccRCC 
management [18].
Recently, by using a retrospective cohort of 20 
formalin-fixed paraffin-embedded (FFPE) tissues, 
we evaluated the levels of specific miRNAs (miR-
21-5p, miR-210-3p, miR185-5p and miR-221-3p) 
differentially expressed in ccRCC vs matched normal 
tissues. We evidenced miR-21-5p and miR-210-3p as 
the most significantly up-regulated in this patient cohort, 
highlighting these onco-miRNAs as possible relevant 
players involved in ccRCC tumorigenesis [19]. To 
further support the potential clinical usefulness of these 
miRNAs in ccRCC management we started a prospective 
study. By using two independent cohorts of patients we 
evidenced that, among the miRNAs previously identified 
as up-regulated in ccRCC tissues, only miR-210-3p 
resulted significantly up-regulated in urine specimens 
collected from 38 ccRCC patients at the time of surgery 
compared to healthy donors samples. Of note, miR-
210-3p levels resulted significantly reduced in follow-
up samples, highlighting this onco-miRNA as potential 
biomarker useful not only for diagnosis but also to assess 
complete resection or response to treatment in ccRCC 
management.
RESULTS
By using a cohort of fresh frozen tissues obtained 
from 10 ccRCC patients undergoing surgical nephrectomy 
resection we evaluated the expression of the same 
miRNAs analyzed in our previous retrospective study 
[19]. The characteristics of ccRCC patients and tumor 
specimens are reported in the Methods section and 
summarized in Table 1. In agreement with the previous 
retrospective study we evidenced that miR-21-5p, 
miR-210-3p and miR-221-3p resulted up-regulated in 
these ccRCC vs matched adjacent normal fresh frozen 
tissues, while miR-185-5p and miR-145-5p did not show 
significant modulation (Figure 1A and Supplementary 
Figure 1A). Our data evidenced that miR-210-3p resulted 
the most significantly up-regulated miRNA in this patients 
cohort (p-value =0.0149) (Figure 1A).
To investigate whether the miRNAs deregulated in 
ccRCC tissues may serve as useful clinical biomarkers, 
we selected miR-21-5p, miR-210-3p and miR-221-
3p to evaluate their expression in 38 urine specimens 
collected at the time of surgery and during follow-up 
(with 15 months as median of time from surgery) from two 
independent cohorts of ccRCC patients; urine specimens 
from healthy donors were analyzed as well.
Of note, miR-210-3p resulted significantly up-
regulated in urine specimens collected from ccRCC 
patients at the time of surgery, compared to healthy 
donors samples (Figure 1B), contrarily to miR-21-5p and 
miR-221-3p, which didn’t show increased levels in urine 
despite their trend of up-regulation observed in tumor 
tissues.
Importantly, miR-210-3p levels resulted signi-
ficantly reduced during follow-up in six ccRCC patients of 
the same cohort, for which follow-up urine samples were 
available (Figure 1C). miR-21-5p and miR-221-3p resulted 
unchanged also in the follow-up samples (Figure 1C).
DISCUSSION
The identification of molecular markers in body 
fluids (e.g., sera and urine), which can be used as non-
invasive diagnostic, prognostic and surveillance markers 
in ccRCC management, is one of the most ambitious 
challenges in oncologic research [20]. Of note, also 
miRNAs are acquiring a great potential as novel cancer 
biomarkers in urological carcinomas [16, 21–25]. To 
date, the increased interest on non-invasive biomarkers, 
allowed by use of novel methodologies (such as 
next generation sequencing, single-cell sequencing 
approaches and digital PCR) has greatly improved the 
translational potential of miRNAs into clinical research 
[16]. However, the development of a standardized 
method considering different methodological drawbacks 
(including samples collection, processing and storage 
or RNA isolation, quantification and normalization) is 
strongly needed to support the strength of circulating 
miRNAs as useful biomarkers in ccRCC management 
[16, 25].
In this study we show that miR-210-3p that was 
previously evidenced as up-regulated in ccRCC vs 
matched normal tissues [19] also show increased levels 
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Table 1: Clinical characteristics of patients with ccRCC
Gender/
age
Weight/
height
(kg/cm)
Smoking
history
Serum 
creatinine
(mg/dl)
Histology
Tumor
grade 
(Fuhrman)
Pathologic
stage
Tumor 
size
(cm)
L. Nodes 
Inv. Metast. Surgery
M/52* 70kgx165cm No 1.11 ccRCC G2 pT2 8.0 Nx Mx Lap. Rad. Right Neph.
F/73** 65kgx160cm No 0.88 ccRCC G2 pT1a 2.0 Nx Mx Lap. Rad. Right Neph.
M/65* 75kg x170cm No 1.00 ccRCC G2 pT1a 2.0 Nx Mx Lap. Part. Right Neph.
M/74** 75kg x165cm No 0.84 ccRCC G2 pT1a nd Nx Mx Lap. Part. Left Neph.
M/84** 90kg x165cm No 0.75 ccRCC G2 pT1a 3.0 Nx Mx Lap. Rad. Right Neph.
M/70* 85kg x170cm Yes 0.99 ccRCC G2 pT3a 7.5 Nx Mx Lap. Rad. Left Neph.
M/70** 78kg x175cm Yes 1.55 ccRCC G2 pT1a 2.5 Nx Mx Lap. Part. Right Neph.
M/42** 60kg x170cm Yes 1.13 ccRCC G2 pT3a 9.5 N0 Mx Lap. Rad. Left Neph.
F/36** 50kg x155cm No 2.70 ccRCC G2 pT1b 5.0 Nx Mx Lap. Rad. Left Neph.
M/81* 80kg x174cm Yes 1.01 ccRCC G2 pT1b 4.3 Nx Mx Lap. Rad. Left Neph.
F/64† 99kg x180cm Yes 1.3 ccRCC G3 pT3a 6 N0 Mx Lap. Rad. Right Neph.
M/74† 73kg x160cm Former 1.21 ccRCC G3 pT1a 3 Nx Mx Lap. Part. Right Rob. Neph.
M/51† 85kg x185cm Former 1.19 ccRCC G3 pT2a 8 N0 Mx Lap. Rad. Left Neph.
M/61† 92kg x165cm Former 1.32 ccRCC G3 pT3b 7 Nx M1 Lap. Rad. Right Rob. Neph.
M/42† n/a Yes 1.36 ccRCC G3 pT3a 7.5 Nx Mx Lap. Rad. Left Neph
M/74† 84kg x183cm No 1.1 ccRCC G3 pT3a 5.4 Nx Mx Lap. Part. Left Rob. Neph.
F/61† n/a n/a 1.06 ccRCC G3 pT3a 5 Nx M1 Lap. Rad. Right. Neph.
F/77† 78kg x165cm No 1.1 ccRCC G4 pT1b 6 Nx Mx Lap. Rad. Left Neph.
M/73† 90kg x175cm No 1.4 ccRCC G3 pT1a 4 Nx Mx Lap. Part. Left Rob. Neph.
M/62† 69kg x164cm No 1.18 ccRCC G2 pT2a 7.2 Nx Mx Lap. Part. Right Rob. Neph.
M/45† 69kg x170cm Yes 1 ccRCC G2 pT1a 2.5 Nx Mx Lap. Part. Right Rob. Neph.
(Continued )
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Gender/
age
Weight/
height
(kg/cm)
Smoking
history
Serum 
creatinine
(mg/dl)
Histology
Tumor
grade 
(Fuhrman)
Pathologic
stage
Tumor 
size
(cm)
L. Nodes 
Inv. Metast. Surgery
F/62† 80kg x160cm No 5.5 ccRCC G2 pT1b 0.88 Nx Mx Lap. Part. Right Rob. Neph.
F/82† 65kg x155cm No 0.66 ccRCC G2 pT1a 3.5 Nx Mx Lap. Part. Right Rob. Neph.
M/53† 71kg x168cm Yes 1.12 ccRCC G4 pT1b 6 Nx M1 Lap. Rad. Left Neph.
F/68† 80kg x160cm Former 0.89 ccRCC G2 pT1b 5 Nx Mx Lap. Part. Left Rob. Neph.
F/64† n/a n/a 1 ccRCC G2 pT1a 3 Nx Mx Lap. Part. Left Rob. Neph.
F/78† n/a n/a 0.86 ccRCC G4 pT3a 7.5 Nx M1 Lap. Rad. Left Neph.
M/52† 60kg x169cm Yes 0.79 ccRCC G3 pT1a 3.5 Nx Mx Lap. Part. Right Rob. Neph.
M/53† n/a n/a 1.3 ccRCC G4 pT3a 11 Nx Mx Lap. Rad. Right Neph.
M/83† 59kg x164cm Yes 1.24 ccRCC G3 pT3a 7.4 Nx Mx Lap. Rad. Left Neph.
M/84† n/a Yes 1.26 ccRCC G4 pT2b 10.2 Nx Mx Lap. Rad. Left Neph.
F/48† n/a n/a 1.12 ccRCC G3 pT1a 3.5 Nx Mx Lap. Part. Left Neph.
M/45† n/a n/a 1.16 ccRCC G2 pT1b 4.2 Nx Mx Lap. Part. Left Rob. Neph.
M/72† n/a n/a 1 ccRCC G3 pT1a 2.5 Nx Mx Lap. Part. Right Rob. Neph.
M/73† n/a n/a 1.08 ccRCC G3 pT1a 2.6 Nx Mx Lap. Part. Right Rob. Neph.
F/49† 62kg x165cm Former 1.2 ccRCC G2 pT1a 3.5 Nx Mx Lap. Rad. Right Neph.
M/45† 80kg x175cm No 1.26 ccRCC G2 pT3a 11 N0 M1 Open Rad. Right Neph.
F/68† 70kg x171cm Yes 1.7 ccRCC G1 pT1b 5.5 Nx Mx Lap. Rad. Right Neph.
M: male; F: female; Metast: metastasis; Nx: regional lymph nodes cannot be assessed; N0: no regional lymph 
node metastasis; Mx: distant metastasis cannot be evaluated; M1: distant metastasis evaluated; Lap: laparoscopic; 
Rad: radical; Neph: nephrectomy; Part: partial; Rob: robotical; N/a: not available; *: Belonging to the first cohort; **: 
Belonging to the first cohort for which also follow-up samples are available; †: Belonging to the second cohort.
in urine specimens from ccRCC patients when compared 
with healthy donors. Of note the urine expression levels 
of miR-21-5p and miR-221-3p resulted unchanged in 
these cohorts of ccRCC patients. These results not only 
support the identification of miR-210-3p as non-invasive 
biomarker for ccRCC management, as also suggested by 
Li and colleagues, but also highlight that only specific 
onco-miRNAs are accumulated in urine specimens of 
ccRCC patients. Of note, the urine level of miR-210-3p 
resulted significantly reduced during follow-up samples 
highlighting this onco-miRNA as potential biomarker 
useful not only for diagnosis but also to assess complete 
resection or response to treatment of ccRCC patients.
In conclusion, this study evidences a number 
of miRNAs, which are altered in ccRCC tissues and 
urine specimens, emerging as putative non-invasive 
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Figure 1: Evaluation of microRNAs levels in fresh frozen tissues and urine specimens from ccRCC patients. (A) Box-
plot showing the modulation of miR-21-5p, miR-210-3p and miR-221-3p in a cohort of 10 matched fresh frozen tissues from ccRCC 
patients. A total of 10 matched ccRCC tumor (T) and adjacent normal tissue (N) samples were analyzed by RT-qPCR. The expression value 
of each miRNA was normalized over the average of SNORD61, SNORD68 and RNU6-2 expression through z-scores method. p-value was 
calculated by paired t-test and a value of P≤0.05(*) was considered statistically significant. (B) Box plots showing the modulation miR-21-
5p, miR-210-3p and miR-221-3p in urine specimens collected from 38 ccRCC patients at the time of surgery (Tumor) and from 10 healthy 
donors samples (Donors) by RT-qPCR and normalized relative to the expression level of Spike-In Control through ΔΔ CT  method. p-value 
was calculated by unpaired t-test and a value of P≤0.01(**) was considered statistically significant. (C) Box plot showing the expression 
level of miR-21-5p, miR-210-3p, miR-221-3p in urine collected from 6 patients at time of surgery (T), during follow-up (15 months as 
median of time from surgery) and from 4 healthy donors samples by RT-qPCR and normalized relative to the expression level of Spike-In 
Control through ΔΔ CT method. p-value was calculated by unpaired t-test and a value of P≤0.05(*) was considered statistically significant.
biomarkers for ccRCC management. Further investigation 
including larger cohorts of patients will allow evaluating 
the associations existing between miRNAs levels and 
insurgence of metastasis, evidencing the strength of these 
biomarkers in the monitoring of tumor progression in 
ccRCC.
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MATERIALS AND METHODS
Patients and urine samples collection
This study includes two independent cohorts of 
ccRCC patients (totally 38 patients) who underwent 
surgical resection between March 2015 and March 2017 
(as described in Table 1). For the 10 ccRCC patients 
of the first cohort, fresh frozen-matched tumoral and 
normal peritumoral kidney tissues were also considered. 
Urine specimens were collected at the time of surgery 
from all the patients; for 6 of the ccRCC patients urine 
was collected also during follow-up (with 15 months as 
median of time from surgery). In particular, urine samples 
were frozen within 30 minutes from collection and stored 
at -80°C until RNA extraction. Patients included in the 
study were not treated with any neo-adjuvant therapy 
before surgery. The surgery procedures performed as 
curative treatment for these patients were: Laparoscopic 
Radical Right or Left Nephrectomy in 20 cases (52,63%), 
Laparoscopic Partial Right or Left Nephrectomy in 17 
cases (44,73%) and Open Radical Right Nephrectomy 
in only 1 case (2,63%). Twenty-five patients were male 
(65.8%) and 13 patients were female (34.2%) with a 
median age of 64.5 years old (range 36-84) and a median 
Serum Creatinin concentration of 1.00 mg/dl (range 
0.66-2.70). All the cases presented a clear cell histotype 
of RCC at the histological examination and according to 
Fuhrman’s grade classification, 19 cases (50%) were G2 
grade, 13 cases (34.21%) were G3 grade, 5 cases (13.16%) 
were G4 grade and only 1 case (2.63%) was G1 grade. As 
main risk factor, smoking habit was taken into account 
in 30 patients for which this information was available; 
among these, 12 patients (40%) were cigarette smokers, 
5 patients (16.67%) have a history of tabagism and 13 
patients (43.33%) were non-smokers (Table 1).
Urine samples were also collected from two 
groups of healthy donors of 4 and 6 individuals with 
characteristics comparable to the ccRCC patients included 
in the study (median age: 60.5; males: 60% and females: 
40%).
RNA extraction and microRNA expression 
analysis
Fresh Frozen samples were homogenized by gentle 
dissociator (Miltenyi Biotec) in 700 μl of Qiazol (Qiagen, 
Chatsworth, CA) and RNA was extracted following the 
manufacturer’s instruction. The concentration and purity 
of total RNA were assessed using a Nanodrop TM 1000 
spectrophotometer (Nanodrop Technologies, Wilmington, 
DE, USA).
A quantity of 150 ng of total RNA was reverse 
transcribed in 20 μl using miScript II RT kit (Qiagen, 
Chatsworth) and 1 μl of cDNA dilution (1:5) was used for 
quantitative Real time PCR (RT-qPCR) experiments.
PCR quantification analysis of the SNORD61, 
SNORD68, RNU6-2 and miRNAs miR-21-5p, miR-
210-3p, miR-221-3p, miR-185-5p and miR-145-5p, 
was performed using the miScript SYBR Green PCR 
kit (Qiagen, Chatsworth) with the miScript Primer 
Assay Hs-SNORD61 (#MS00033705), SNORD68 
(#MS00033712), RNU6B-2 (#MS00033740), Hs-miR-
21-5p (#MS00009079), Hs-miR-210-3p (#MS00003801), 
Hs-miR-221-3p (#MS00003857), Hs-miR-185-5p 
(#MS00003647) and Hs-miR-145-5p (#MS00003528) 
(Qiagen, Chatsworth, CA, USA). All reactions were 
performed in triplicate. Data were analyzed by quantitative 
Real time PCR relative to a standard curve; standard curve 
was performed with serial dilution of a reference cDNA 
obtained from RNA extracted from a tumor sample. For 
the analysis z-score were calculated for all expression 
value to standardize the data. Subsequently, z-score values 
of SNORD61, SNORD68, RNU6-2 were averaged and 
used to normalize the expression values of each miRNA. 
The p value was calculated by using a parametric test with 
paired data.
Total RNA from 200 μl of urine samples was 
extracted using miRNAeasy serum/plasma kit (Qiagen, 
Chatsworth, CA) following the manufacturer’s instructions. 
The concentration purity and quality of total RNA were 
assessed using a Nanodrop TM 1000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE, USA). A 
quantity of 25 ng of total RNA was reverse transcribed 
in 10 μl using miScript II RT kit (Qiagen, Chatsworth) 
and 1 μl of cDNA dilution (1:5) was used for quantitative 
Real time PCR (RT-qPCR) experiments. Quantification of 
miRNAs miR-21-5p, miR-210-3p, miR-221-3p was carried 
out by miScript Primer Assay (Qiagen, Chatsworth, CA), 
normalizing over the Spike-In Control (#219610) (Qiagen, 
Chatsworth, CA) through ΔΔCT method and using the 
miScript SYBR Green PCR kit (Qiagen, Chatsworth, CA). 
All reactions were performed in triplicate. microRNA 
expression was evaluated on urine samples from each of 
the two ccRCC cohorts and compared to that of the two 
groups of urine samples from healthy donors (first cohort 
vs. 4 donors; second cohort vs. 6 donors). Data were then 
collected and presented in box plots.
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